Skip to content
Inciteful Med
Resources About us Ask a Question

SFT Follow-Up Schedule: How Often Do I Need Scans?

Published: | Updated:

Unlike many other cancers, solitary fibrous tumors (SFTs) require lifelong imaging scans because they can return more than a decade after treatment. Most patients have scans every 3 to 6 months initially, then transition to annual scans based on their individual risk score.

Key Takeaways

  • • Solitary fibrous tumors require lifelong surveillance scans because they have a known risk of recurring many years after initial treatment.
  • • Your specific scan schedule is customized based on your tumor's risk score, location, and whether surgical margins were clear.
  • • Most patients undergo scans every 3 to 6 months for the first few years before transitioning to an annual imaging schedule.
  • • Depending on where your tumor was located, your doctor will order CT scans, MRI scans, or PET scans to monitor for any changes.
  • • Because of the rarity and unpredictable nature of SFT, it is highly recommended to keep a sarcoma specialist involved in your care indefinitely.

Because solitary fibrous tumors (SFTs) behave differently than many other tumors, your follow-up schedule will look different than standard cancer surveillance. After you finish treatment, you will need imaging scans for the rest of your life [1][2]. While specific schedules are tailored to your individual risk level, most patients have scans every 3 to 6 months for the first few years [3][4]. If those scans remain clear, the frequency usually transitions to once a year [5][6].

Why SFT Requires Lifelong Monitoring

For many types of cancer, patients are officially “discharged” from their oncologist’s care after five years of clear scans. Solitary fibrous tumor is an exception to this rule. SFTs have an unpredictable nature and a known potential for late recurrence [7][8]. Even tumors that appear completely benign under a microscope can sometimes return or spread to other parts of the body (metastasize) more than a decade after the original surgery [9][10].

Because of this risk of late recurrence, clinical guidelines and sarcoma experts universally recommend lifelong surveillance for all SFT patients, regardless of how low-risk their initial tumor appeared [11][12][13]. Fortunately, if a scan does detect a recurrence, finding it early means you have more options—such as another surgery or targeted therapies—to manage it effectively.

How Risk Levels Guide Your Schedule

There is no single universal schedule that applies to every SFT patient [14]. Instead, your medical team will create a customized surveillance plan based on your individual risk of recurrence [15][16]. Doctors often use scoring systems (like the Demicco risk score) that look at your age, the size of your tumor, how actively the tumor cells were dividing (the mitotic rate), and the presence of tumor necrosis (areas of dead cells inside the tumor) [17][16].

  • High-Risk Tumors: If your tumor had a high risk score, positive surgical margins (meaning some tumor cells may have been left behind), or certain genetic markers like a TERT promoter mutation (a specific change in the tumor’s DNA that allows cells to divide more aggressively), your doctor will likely recommend more intensive monitoring [18][19]. You may need scans every 3 to 4 months for a longer period before moving to a less frequent schedule.
  • Low-Risk Tumors: Even if your tumor was small, fully removed, and classified as low-risk, you will still need regular check-ups [11]. You might start with scans every 6 months for the first few years, eventually shifting to annual scans indefinitely [3][6].

What Types of Scans Will I Need?

The type of imaging you receive depends entirely on where your primary tumor was located, as well as where SFTs are most likely to spread (commonly the lungs, liver, or bones) [20][21]. Surveillance strategies must monitor for both local recurrence (the tumor coming back in the original spot) and distant metastasis (spreading to other organs) [16][22].

  • CT Scans: If your tumor was located in the chest (pleura) or abdomen, computed tomography (CT) scans are the standard choice [20][23].
  • MRI Scans: If your SFT was intracranial (in the brain or spinal cord), in your pelvis, or in your soft tissues, Magnetic Resonance Imaging (MRI) is often preferred because it provides detailed views of soft tissues and nerves [24][25].
  • PET Scans: While not always part of routine follow-up, an FDG-PET/CT scan may be used if your doctor suspects the tumor has spread or needs to investigate something seen on a standard CT or MRI [26][27].

These scans often require IV contrast dye to help the radiologist see the tissues more clearly. Note that there is no specific blood test or “tumor marker” used to monitor SFT; doctors rely strictly on these imaging scans to keep track of your health.

Between Scans: Symptoms and Your Care Team

While scans are the most important tool, you should also pay attention to your body. Depending on where your original tumor was, contact your doctor if you notice new or persistent physical symptoms, such as an unexplained lump, continuous pain, or shortness of breath, before your next scheduled scan.

Because SFT is very rare and requires unique, lifelong monitoring, it is highly recommended to keep a sarcoma specialist involved in your care indefinitely. While a local general oncologist or primary care doctor might order your routine annual scans, having a sarcoma expert review the results ensures your specialized needs are not overlooked as the years go by.

Living with a schedule of lifelong scans can cause anxiety (often called “scanxiety”), but this careful monitoring is your best tool for staying healthy. Catching any changes early gives you and your team the best chance to manage them effectively.

Frequently Asked Questions

How long do I need follow-up scans after SFT treatment?
You will need lifelong surveillance scans. Because solitary fibrous tumors can sometimes recur or spread more than a decade after the original treatment, clinical guidelines universally recommend indefinite monitoring for all patients.
What determines my SFT scan schedule?
Your customized schedule is based on your individual risk of recurrence. Doctors use scoring systems, like the Demicco risk score, which factor in your age, tumor size, mitotic rate, and the presence of tumor necrosis to decide how frequently you need scans.
What type of imaging scans are used to monitor SFT?
The type of scan depends on where your primary tumor was located. CT scans are typical for chest or abdominal tumors, while MRI scans are generally preferred for brain, spinal, pelvic, or soft tissue tumors because they provide detailed views of nerves and tissues.
Do I still need scans if my SFT was considered low-risk?
Yes. Even if your tumor was small, completely removed, and classified as low-risk, you still need regular check-ups. You will likely transition to annual scans after the first few years, but the lifelong monitoring rule still applies.
Who should manage my long-term SFT follow-up care?
Because solitary fibrous tumors are very rare and behave differently from common cancers, it is highly recommended to have a dedicated sarcoma specialist oversee your care. They can ensure your specialized needs are met as the years go by.

Questions for Your Doctor

  • • What was my Demicco risk score, and how exactly does it dictate my specific scan schedule?
  • • Were my surgical margins completely clear, or were they positive/close, requiring closer monitoring of the surgical site?
  • • Who will be responsible for ordering and interpreting my scans 5, 10, or 15 years from now?
  • • Will my CT or MRI scans require IV contrast dye every time?
  • • What specific physical symptoms should prompt me to call your office before my next scheduled scan?

Questions for You

  • • What physical symptoms did I experience before my initial diagnosis that I should be on the lookout for now?
  • • Do I feel comfortable with the level of rare sarcoma expertise my current care team provides, or should I establish a connection with a dedicated sarcoma center?
  • • How can I manage my schedule and mental health to cope with the 'scanxiety' that comes with lifelong surveillance?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Prostatic Solitary Fibrous Tumor With Pulmonary Metastases: A Case Report.

    Kaygusuz Y, Kus F, Yilmaz F, et al.

    Cureus 2025; (17(10)):e94849 doi:10.7759/cureus.94849.

    PMID: 41257096
  2. 2

    Grade III solitary fibrous tumor/hemangiopericytoma: An enthralling intracranial tumor-A case report and literature review.

    Al Armashi AR, Alkrekshi A, Al Zubaidi A, et al.

    Radiology case reports 2022; (17(10)):3792-3796 doi:10.1016/j.radcr.2022.07.007.

    PMID: 35965927
  3. 3

    Malignant extrapleural solitary fibrous tumor arising in the sublingual gland: A case report and review of literature.

    Iorio B, Ronchi A, Montella M, et al.

    Oral oncology 2019; (90()):141-144 doi:10.1016/j.oraloncology.2018.12.013.

    PMID: 30638760
  4. 4

    Solitary fibrous tumor with atypical features of the paravesical space: benign clinical course at the 10-years follow-up. Report of a case and review of the literature.

    Magro G, Salvatorelli L, Piombino E, et al.

    Pathologica 2020; (112(4)):200-209 doi:10.32074/1591-951X-126.

    PMID: 33393523
  5. 5

    Solitary fibrous tumor of the greater omentum mimicking an ovarian tumor in a young woman.

    Rodriguez Tarrega E, Hidalgo Mora JJ, Paya Amate V, Vega Oomen O

    Gynecologic oncology reports 2016; (17()):16-9 doi:10.1016/j.gore.2016.04.004.

    PMID: 27354994
  6. 6

    Solitary fibrous tumor of the ilium: A case report.

    Ge X, Liao J, Choo RJ, et al.

    Medicine 2017; (96(51)):e9355 doi:10.1097/MD.0000000000009355.

    PMID: 29390521
  7. 7

    Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature.

    Lavacchi D, Antonuzzo L, Briganti V, et al.

    Anti-cancer drugs 2020; (31(6)):646-651 doi:10.1097/CAD.0000000000000900.

    PMID: 31972591
  8. 8

    A Rare Case of Metastatic Solitary Fibrous Tumor (Hemangiopericytoma) of the Dura on 18F-FDG PET/CT.

    Grünig H, Skawran S, Stolzmann P, et al.

    Clinical nuclear medicine 2021; (46(9)):768-769 doi:10.1097/RLU.0000000000003626.

    PMID: 34288634
  9. 9

    A Rare Case of Solitary Fibrous Tumor Involving the Nasolacrimal Duct System in a 12-Year-Old Female: A Case Report and Review of the Literature.

    Sheth NT, Adetunji MO, Smith ET, et al.

    Ophthalmic plastic and reconstructive surgery 2025; (41(3)):e89-e95 doi:10.1097/IOP.0000000000002854.

    PMID: 39700394
  10. 10

    A rare mesenchymal neoplasm at unusual location: Solitary fibrous tumor of vulva.

    Nag G, Rao SR

    Gynecologic oncology reports 2015; (12()):52-4 doi:10.1016/j.gore.2015.03.002.

    PMID: 26076159
  11. 11

    Malignant Solitary Fibrous Tumor of the Right Cerebellum: A Case Report.

    Zhu YT, Liu Y, Chen LG, Song DP

    Case reports in neurology 2021; (13(1)):259-266 doi:10.1159/000510844.

    PMID: 34054465
  12. 12

    Malignant solitary fibrous tumor in the central nervous system treated with surgery, radiotherapy and anlotinib: A case report.

    Zhang DY, Su L, Wang YW

    World journal of clinical cases 2022; (10(2)):631-642 doi:10.12998/wjcc.v10.i2.631.

    PMID: 35097089
  13. 13

    Malignant recurrent orbital solitary fibrous tumor.

    Pol JN, Patil DB, Desai SS, Calcuttawala AB

    Indian journal of pathology & microbiology 2023; (66(4)):819-822 doi:10.4103/ijpm.ijpm_713_21.

    PMID: 38084539
  14. 14

    Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients.

    Macagno N, Vogels R, Appay R, et al.

    Brain pathology (Zurich, Switzerland) 2019; (29(1)):18-27 doi:10.1111/bpa.12613.

    PMID: 29600523
  15. 15

    Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System.

    Kinslow CJ, Rae AI, Kumar P, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030876.

    PMID: 36765837
  16. 16

    Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.

    Sagiv O, Bell D, Guo Y, et al.

    Ophthalmic plastic and reconstructive surgery 2019; (35(2)):148-154 doi:10.1097/IOP.0000000000001189.

    PMID: 30371551
  17. 17

    Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

    Demicco EG, Wagner MJ, Maki RG, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(10)):1433-1442 doi:10.1038/modpathol.2017.54.

    PMID: 28731041
  18. 18

    TERT promoter mutations and prognosis in solitary fibrous tumor.

    Bahrami A, Lee S, Schaefer IM, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(12)):1511-1522 doi:10.1038/modpathol.2016.126.

    PMID: 27562490
  19. 19

    Intradural-Extramedullary Solitary Fibrous Tumor/Hemangiopericytoma with a Negative Result on Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography.

    Tomomatsu Y, Iizuka Y, Mieda T, et al.

    Case reports in orthopedics 2019; (2019()):3926903 doi:10.1155/2019/3926903.

    PMID: 31885980
  20. 20

    Solitary Fibrous Tumors of the Chest: An Analysis of Fifty Patients.

    Zhang J, Liu J, Zhang Z, Tian B

    Frontiers in oncology 2021; (11()):697156 doi:10.3389/fonc.2021.697156.

    PMID: 34277442
  21. 21

    Solitary Fibrous Tumor of the Bone Detected by FDG PET/CT.

    Li J, Kuang A, Shen G

    Clinical nuclear medicine 2022; (47(10)):e660-e662 doi:10.1097/RLU.0000000000004290.

    PMID: 35619204
  22. 22

    Bulky cardiac metastasis of intracranial solitary fibrous tumor/hemangiopericytoma: Delayed metastasis after cranial tumor resection.

    Hashida S, Yokota H, Oyama Y, et al.

    Radiology case reports 2019; (14(10)):1175-1180 doi:10.1016/j.radcr.2019.06.030.

    PMID: 31372191
  23. 23

    Solitary fibrous tumor of the scrotum: a case report and review of the literature.

    Chang TH, Chen M, Lee CC

    BMC urology 2019; (19(1)):138 doi:10.1186/s12894-019-0573-2.

    PMID: 31888599
  24. 24

    Cystic intracranial solitary fibrous tumor: a case report.

    Li Y, Li D, Yang L, et al.

    Frontiers in oncology 2024; (14()):1422779 doi:10.3389/fonc.2024.1422779.

    PMID: 39015488
  25. 25

    Are bone erosion and peripheral feeding vessels hallmarks of intracranial solitary fibrous tumor/hemangiopericytoma?

    Sugiyama H, Tsutsumi S, Hashizume A, et al.

    Radiology case reports 2022; (17(8)):2702-2707 doi:10.1016/j.radcr.2022.04.050.

    PMID: 35669225
  26. 26

    Intracranial Solitary Fibrous Tumor: A "New" Challenge for PET Radiopharmaceuticals.

    Sardaro A, Mammucci P, Pisani AR, et al.

    Journal of clinical medicine 2022; (11(16)) doi:10.3390/jcm11164746.

    PMID: 36012988
  27. 27

    Cardiac solitary fibrous tumor - an extremely rare but potentially fatal diagnosis.

    Szot M, Zub A, Kurzawa P, et al.

    Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery 2024; (21(1)):39-42 doi:10.5114/kitp.2024.138574.

    PMID: 38693991

This page explains follow-up care and surveillance schedules for solitary fibrous tumors for educational purposes only. Always consult your sarcoma specialist or oncologist to determine the best monitoring plan for your specific situation.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.